TY - JOUR
T1 - Distinction and prognosis of early arthritis phenotypes
T2 - an analysis in three European cohorts
AU - Sepriano, Alexandre
AU - van Dijk, Bastiaan
AU - Ramiro, Sofia
AU - van der Helm-van Mil, Annette
AU - Combe, Bernard
AU - van Schaardenburg, Dirkjan
AU - de Wit, Maarten
AU - Kent, Alison
AU - Mateus, Elsa
AU - Landewé, Robert
N1 - Funding Information: This study was supported by a grant of the Foundation for Research in Rheumatology (FOREUM), under the topic call on Innovative Medicine 2019 (project ID: 036). ESPOIR Funding: An unrestricted grant from Merck Sharp and Dohme (MSD) was allocated for the first 5 years of the cohort study. Two additional grants from INSERM supported part of the biological database. The French Society of Rheumatology, Abbvie, Pfizer, Lilly and more recently Fresenius and Galapagos supported the ESPOIR cohort study. Funding Information: AS: speaking and/or consulting fees from Abbvie, Novartis, UCB and Lilly. Bastiaan van Dijk: None. Sofia Ramiro: research grants and/or consultancy fees: AbbVie, Eli Lilly, Galapagos, MSD, Novartis, Pfizer, UCB, Sanofi. AvdH: None. BC: consulting fees from AbbVie, Celltrion, Chugaï, Eli-Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer. DvS: speaking fees from Janssen, Galapagos. MdW: Over the last three years Stichting Tools has received fees for lectures or consultancy provided by MdW from Celgene, Eli Lilly, Pfizer and UCB. Alison Kent: None. EF-M: Consulting fees from Boehringer Ingelheim Portugal. Over the last three years, the Portuguese League Against Rheumatic Diseases (LPCDR) received non-financial and financial support from AbbVie, A. Menarini Portugal—Farmacêutica, S.A., Amgen Biofarmacêutica, Grünenthal S.A., GSK, Lilly Portugal, Medac, MSD, Novartis, Pfizer, Roche. RL: Received consulting fees from AbbVie, BMS, Celgene, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Roche, UCB and is Director of Rheumatology Consultancy bv Funding Information: This study was supported by a grant of the Foundation for Research in Rheumatology (FOREUM), under the topic call on Innovative Medicine 2019 (project ID: 036). ESPOIR Funding: An unrestricted grant from Merck Sharp and Dohme (MSD) was allocated for the first 5 years of the cohort study. Two additional grants from INSERM supported part of the biological database. The French Society of Rheumatology, Abbvie, Pfizer, Lilly and more recently Fresenius and Galapagos supported the ESPOIR cohort study. Publisher Copyright: © Author(s) (or their employer(s)) 2023.
PY - 2023/11/1
Y1 - 2023/11/1
N2 - OBJECTIVES: The objective of this study is to evaluate whether there are differences in the long-term prognosis across various phenotypes of early arthritis (EA). METHODS: Three EA cohorts (Reade, Etude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) and Early Arthritis Clinic (EAC)) were analysed. Clinical data were collected up to 24 years. Hands and feet radiographs were scored according to the Sharp van der Heijde (SvdH) method. Latent class analysis was applied to determine the EA phenotypes at baseline. Each class received a label reflecting its most prominent features. Prognostic outcomes included Health Assessment Questionnaire (HAQ), Short Form 36 (SF36) and SvdH score. The association between class membership and outcomes over time was tested in multivariable models. RESULTS: In total, 390 (Reade), 798 (ESPOIR) and 3991 (EAC) patients were analysed separately. Two classes with symmetrical polyarthritis emerged; one of these labelled as autoimmune inflammatory polyarthritis (AIPA), had high likelihood of acute phase reactants (APR) elevation and autoantibody positivity, while the other (mild-inflammatory polyarthritis; MIPA) had not. A third class had oligoarthritis of upper limbs (OAUL) and could be subdivided into autoimmune OAUL and mild-inflammatory OAUL. A fifth class had oligoarthritis of lower limbs. The SvdH scores were worse in patients with APR/autoantibodies (AIPA) than in those without (MIPA). No clinically meaningful differences across classes in HAQ or SF36 over time were found. CONCLUSION: Radiographic progression over time primarily occurs in EA patients with APR/autoantibodies. The absence of these markers, however, does not necessarily translate into better long-term function and quality of life. Clinicians should not only aim at preventing joint damage, but look beyond structural progression in order to further improve the lives of people with EA.
AB - OBJECTIVES: The objective of this study is to evaluate whether there are differences in the long-term prognosis across various phenotypes of early arthritis (EA). METHODS: Three EA cohorts (Reade, Etude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) and Early Arthritis Clinic (EAC)) were analysed. Clinical data were collected up to 24 years. Hands and feet radiographs were scored according to the Sharp van der Heijde (SvdH) method. Latent class analysis was applied to determine the EA phenotypes at baseline. Each class received a label reflecting its most prominent features. Prognostic outcomes included Health Assessment Questionnaire (HAQ), Short Form 36 (SF36) and SvdH score. The association between class membership and outcomes over time was tested in multivariable models. RESULTS: In total, 390 (Reade), 798 (ESPOIR) and 3991 (EAC) patients were analysed separately. Two classes with symmetrical polyarthritis emerged; one of these labelled as autoimmune inflammatory polyarthritis (AIPA), had high likelihood of acute phase reactants (APR) elevation and autoantibody positivity, while the other (mild-inflammatory polyarthritis; MIPA) had not. A third class had oligoarthritis of upper limbs (OAUL) and could be subdivided into autoimmune OAUL and mild-inflammatory OAUL. A fifth class had oligoarthritis of lower limbs. The SvdH scores were worse in patients with APR/autoantibodies (AIPA) than in those without (MIPA). No clinically meaningful differences across classes in HAQ or SF36 over time were found. CONCLUSION: Radiographic progression over time primarily occurs in EA patients with APR/autoantibodies. The absence of these markers, however, does not necessarily translate into better long-term function and quality of life. Clinicians should not only aim at preventing joint damage, but look beyond structural progression in order to further improve the lives of people with EA.
KW - Arthritis, Rheumatoid
KW - Magnetic Resonance Imaging
KW - Outcome and Process Assessment, Health Care
UR - http://www.scopus.com/inward/record.url?scp=85175769850&partnerID=8YFLogxK
U2 - https://doi.org/10.1136/rmdopen-2023-003611
DO - https://doi.org/10.1136/rmdopen-2023-003611
M3 - Article
C2 - 37914180
SN - 2056-5933
VL - 9
JO - RMD OPEN
JF - RMD OPEN
IS - 4
M1 - e003611
ER -